Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
| Autor: | P. Trunet, Francesco Scaglione, G. Bisagni, G. Cocconi, Ch. Pfister, Franco Fraschini |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
medicine.medical_specialty Hydrocortisone Estrone medicine.drug_class medicine.medical_treatment Urology Antineoplastic Agents Breast Neoplasms Pilot Projects chemistry.chemical_compound Internal medicine Nitriles medicine Humans Endocrine system Enzyme Inhibitors Aldosterone Aged Chemotherapy Aromatase inhibitor Estradiol Aromatase Inhibitors business.industry Letrozole Cancer Hematology Middle Aged Triazoles medicine.disease Metastatic breast cancer Endocrinology Oncology chemistry Estrogen Female business medicine.drug |
| Zdroj: | Annals of Oncology. 7:99-102 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/oxfordjournals.annonc.a010490 |
| Popis: | 3Ciba-Geigy, Basel, Switzerland Summary Purpose: To evaluate the endocrine effects as well as the pharmacokinetic parameters, efficacy and safety of letrozole, a new fourth-generation non-steroidal aromatase inhibitor. Patients and methods: Fourteen postmenopausal women with progressive metastatic breast cancer, previously treated with endocrine therapy and/or chemotherapy for advanced disease, were treated with 0.5 mg daily doses of letrozole, orally. Endocrine and pharmacokinetic measurements were made before treatment and on days 14, 28, 56, and 84 of therapy. Results: Letrozole induced a >86% decrease in plasma estrone and a => 67% reduction in circulating estradiol from day 14 on. There was a statistically significant decrease in plasma cortisol, which appeared clinically irrelevant since all values remained within the normal range. No significant changes in aldosterone concentration were noted. One patient achieved a complete response (CR) and 4 patients a partial response (PR), with an objective response rate of 36% (95% CI13% to 65%). Median duration of response was 24 months, ranging from 4 to 44 months. No toxic effects attributable to letrozole were noted in any patient. Conclusion: Letrozole appears to be a very promising new antiaromatase drug. The characteristics of the patients more likely to respond, taking into account prior systemic treatment, should be defined by future studies. Further phase n and phase HI studies comparing letrozole to other available second or even first-line endocrine-therapy agents, are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|